Equities

Bioretec Oy

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Bioretec Oy

Actions
Health CareMedical Equipment and Services
  • Price (EUR)0.300
  • Today's Change0.028 / 10.29%
  • Shares traded100.13k
  • 1 Year change-87.32%
  • Beta-0.1687
Data delayed at least 15 minutes, as of Feb 16 2026 12:06 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Bioretec Oy is a Finland-based medical device manufacturer company focusing on the development of strong, safe and reliable bioresorbable implants for pediatric and adult orthopedics. The Company operates as a developer, manufacturer and commercializer of innovative bioresorbable orthopedic implants and implant materials used for the treatment of bone and soft tissue injuries. Bioretec Oy’s existing Activa product portfolio consists of bioabsorbable biopolymer products that are alreadyavailable in the market for applications in pediatrics, trauma surgery as well as sports surgery. Bioretec Oy has one Germany-based subsidiary, BRI.Tech GmbH. The Company’s products are used all over the world.

  • Revenue in EUR (TTM)--
  • Net income in EUR--
  • Incorporated1998
  • Employees57.00
  • Location
    Bioretec OyYrittajankulma 5TAMPERE 33710FinlandFIN
  • Phone+358 207789500
  • Fax+358 33170225
  • Websitehttps://bioretec.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SpectraCure AB (publ)134.28k-5.02m5.16m13.00--0.393--38.43-0.165-0.1650.00520.24680.012--1.90109,384.60-44.68-13.14-49.10-14.07835.02243.69-3,739.03-592.49---197.290.0325---46.15-13.97-12.54--0.1962--
ScandiDos AB5.61m-130.41k5.34m25.00--1.3191.660.9526-0.0242-0.02421.040.75760.84161.525.602,283,539.00-1.96-8.71-3.04-14.6848.3052.29-2.33-10.670.7927--0.00--2.341.55102.23---11.62--
Luxbright AB1.08m-1.82m5.41m12.00--2.13--4.99-0.1644-0.16440.09680.20670.27887.732.68---46.74-56.30-59.61-66.28-6.22-79.12-167.60-450.361.22-83.810.1076--26.5279.40-9.86------
Kontigo Care AB2.75m-195.85k5.54m10.00--1.1616.222.02-0.0589-0.05890.82621.430.4487--7.97---3.190.296-3.980.4064125.51129.99-7.120.4638----0.00---3.667.41-367.61--17.15--
Episurf Medical AB1.52m-5.49m5.78m18.00--1.29--3.80-0.0533-0.05330.01380.02860.2043--4.54894,444.40-72.97-47.42-86.27-52.18-----357.14-701.121.41-579.000.0935--22.9018.1323.42--7.81--
Neola Medical AB0.00-1.04m5.80m8.00--0.7829-----0.1479-0.14790.001.010.00----0.00-13.81-15.62-14.65-16.86--5,384.30---6,523.935.61--0.00-------11.70--35.63--
Redsense Medical AB (publ)2.90m28.52k6.89m4.00221.672.03123.552.380.020.021.862.180.76971.966.616,134,600.000.7578-14.280.8514-15.8661.4568.850.9846-32.794.69--0.00--12.8516.26107.58---53.01--
Scandinavian ChemoTech AB1.10m-821.46k7.21m1.00--13.27--6.54-0.3727-0.37270.50030.26530.7270.59172.661,946,333.00-54.15-92.70-83.07-131.4682.15104.65-74.49-866.060.861-5.610.00--132.6763.8534.96---59.68--
BibbInstruments AB14.07k-1.26m8.19m4.00--2.03--582.38-0.3802-0.38020.00411.050.00382.062.7137,250.00-33.98-36.85-35.53-40.0630.8759.14-8,922.82-22,555.646.67--0.00-------15.85---1.52--
Bioretec Oy-100.00bn-100.00bn8.37m57.00---------------------------57.56---77.31--70.90---128.20--------16.3221.07-21.78------
SyntheticMR AB (publ)5.39m-5.19m9.28m41.00--0.6659--1.72-0.9057-0.90570.94671.650.3678--0.87331,391,415.00-35.42-7.92-51.34-10.5110.4156.07-96.28-14.37---8.730.0450--2.473.20-241.50--7.37--
Iconovo AB149.85k-3.89m9.90m19.00--0.4425--66.06-1.67-1.670.05372.460.0117--0.260863,475.20-30.39-28.39-33.14-31.51901.69159.24-2,598.41-295.86---138.020.0391---58.55-24.2210.36--22.28--
Observe Medical ASA1.49m-10.95m9.90m4.00--4.29--6.66-26.57-26.573.290.19090.11182.878.293,350,800.00-82.38-42.22-205.00-64.146.2430.17-737.14-327.970.1175-3.720.9572---33.85153.47-98.73---2.97--
Arcoma AB12.55m410.87k10.54m31.0024.331.529.630.83950.32050.32059.875.131.452.9213.714,288,452.004.752.166.663.7540.4537.953.271.402.04--0.000.00-3.813.24336.0011.08-9.43--
Immunovia AB (publ)74.13k-11.85m11.36m9.00------153.21-0.3569-0.35690.0024-0.0210.0156--0.26487,222.22-249.16-48.08-827.53-52.27-7,231.59-6,932.30-15,989.68-17,625.510.6282-3.001.68---40.8921.2075.26------
Data as of Feb 16 2026. Currency figures normalised to Bioretec Oy's reporting currency: Euro EUR

Institutional shareholders

27.11%Per cent of shares held by top holders
HolderShares% Held
Keskin�inen El�kevakuutusyhti� Ilmarinenas of 31 Mar 20251.83m5.94%
Evli Fund Management Co. Ltd.as of 30 Jan 20261.25m4.07%
Sp-Fund Management Co. Ltd.as of 30 Jan 20261.17m3.81%
Keskin�inen Ty�el�kevakuutusyhti� Eloas of 31 Mar 2025802.22k2.61%
Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 31 Mar 2025704.67k2.29%
Danske Bank A/S (Investment Management Finland)as of 31 Mar 2025672.44k2.18%
Handelsbanken Fonder ABas of 31 Jan 2026595.21k1.93%
OP Asset Management Ltd.as of 31 Mar 2025532.42k1.73%
eQ Varainhoito Oyas of 31 Mar 2025444.67k1.45%
Schroder Investment Management (Europe) SA (Finland)as of 30 Jun 2025337.00k1.10%
More ▼
Data from 01 Jan 1960 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.